Has John Barton, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,805 in general payments to John Barton, MD across 310 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Barton, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Barton, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Barton, MD

Emergency Medicine · Slidell, LANPI 1841233095

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 310 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Among emergency medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,805in general payments, 2019–2025

Across 310 payments — averaging $15.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$866
Sunovion Pharmaceuticals Inc.$614
Regeneron Healthcare Solutions, Inc.$497
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$447
Takeda Pharmaceuticals U.S.A., Inc.$333
Lilly USA, LLC$326
plus $2K from 23 others

What the payments were for

Food & beverage$4,803100%
Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	60	$866
Sunovion Pharmaceuticals Inc.	50	$614
Regeneron Healthcare Solutions, Inc.	30	$497
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	31	$447
Takeda Pharmaceuticals U.S.A., Inc.	19	$333
Lilly USA, LLC	19	$326
Otsuka America Pharmaceutical, Inc.	17	$301
Pfizer	16	$281
Axsome Therapeutics, Inc.	11	$185
Idorsia Pharmaceuticals US Inc	12	$168
GSK	5	$98
AstraZeneca	6	$92
UCB, Inc.	5	$88
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	4	$71
Johnson & Johnson	3	$60
Novartis	3	$41
Merz North America, Inc.	2	$40
Tolmar, Inc.	2	$39
Azurity Pharmaceuticals, Inc.	2	$36
Novo Nordisk	2	$36
Phathom Pharmaceuticals, Inc.	2	$34
Adlon Therapeutics L.p.	2	$33
Eisai Inc.	1	$25
Supernus Pharmaceuticals, Inc.	1	$21
Antares Pharma, Inc.	1	$20
Biohaven Pharmaceuticals, Inc.	1	$14
Lundbeck LLC	1	$14
Merck	1	$14
Mylan Specialty L.p.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

VRAYLAR$125

How this compares

$4,805 in reported general payments places this provider in the 95th percentile of 881 emergency medicine providers in Louisiana.

See all emergency medicine providers in Louisiana →

Medicare billing

Part B allowed, 2024

$64,902

Medicare patients

195

Services billed

560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	90	$112,437
MounjaroTirzepatide	81	$92,167
TrintellixVortioxetine Hydrobromide	38	$27,328
EliquisApixaban	19	$27,118
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	41	$25,596
FarxigaDapagliflozin Propanediol	30	$21,655
TrulicityDulaglutide	13	$21,468
Nurtec OdtRimegepant Sulfate	11	$20,502
JanumetSitagliptin Phos/Metformin Hcl	17	$14,504
LinzessLinaclotide	22	$12,394
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	334	$9,408
Tresiba Flextouch U-100Insulin Degludec	14	$8,541
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	545	$8,360
SymbicortBudesonide/Formoterol Fumarate	17	$4,507
Albuterol Sulfate HfaAlbuterol Sulfate	158	$4,482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity	$326	$113,63494 claims
Novo NordiskOzempic	$36	$112,43790 claims
PfizerEliquis, Nurtec Odt	$281	$47,62030 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix	$333	$27,32838 claims
AstraZenecaFarxiga, Symbicort	$92	$26,16247 claims
GSKTrelegy Ellipta	$98	$25,59641 claims
MerckJanumet	$14	$14,50417 claims
AbbVieLinzess	$866	$12,39422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 881 emergency medicine providers in Louisiana.